全文获取类型
| 收费全文 | 2275篇 |
| 免费 | 403篇 |
| 国内免费 | 55篇 |
专业分类
| 农学 | 7篇 |
| 基础科学 | 2篇 |
| 综合类 | 140篇 |
| 农作物 | 1篇 |
| 水产渔业 | 3篇 |
| 畜牧兽医 | 2579篇 |
| 植物保护 | 1篇 |
出版年
| 2024年 | 7篇 |
| 2023年 | 112篇 |
| 2022年 | 38篇 |
| 2021年 | 129篇 |
| 2020年 | 199篇 |
| 2019年 | 206篇 |
| 2018年 | 141篇 |
| 2017年 | 134篇 |
| 2016年 | 139篇 |
| 2015年 | 171篇 |
| 2014年 | 155篇 |
| 2013年 | 114篇 |
| 2012年 | 118篇 |
| 2011年 | 92篇 |
| 2010年 | 81篇 |
| 2009年 | 83篇 |
| 2008年 | 72篇 |
| 2007年 | 96篇 |
| 2006年 | 63篇 |
| 2005年 | 59篇 |
| 2004年 | 74篇 |
| 2003年 | 60篇 |
| 2002年 | 43篇 |
| 2001年 | 47篇 |
| 2000年 | 40篇 |
| 1999年 | 34篇 |
| 1998年 | 29篇 |
| 1997年 | 21篇 |
| 1996年 | 21篇 |
| 1995年 | 17篇 |
| 1994年 | 14篇 |
| 1993年 | 20篇 |
| 1992年 | 16篇 |
| 1991年 | 8篇 |
| 1990年 | 13篇 |
| 1989年 | 13篇 |
| 1988年 | 10篇 |
| 1987年 | 9篇 |
| 1986年 | 8篇 |
| 1985年 | 6篇 |
| 1984年 | 5篇 |
| 1983年 | 2篇 |
| 1982年 | 2篇 |
| 1981年 | 3篇 |
| 1980年 | 4篇 |
| 1978年 | 2篇 |
| 1977年 | 1篇 |
| 1956年 | 2篇 |
排序方式： 共有2733条查询结果，搜索用时 15 毫秒
31.
Association of hyponatremia and hyperglycemia with outcome in dogs with congestive heart failure 总被引：1，自引：0，他引：1
Colleen A. Brady DVM DACVECC Dez Hughes BVSc MRCVS DACVECC Kenneth J. Drobatz DVM MSCE DACVECC DACVIM 《Journal of Veterinary Emergency and Critical Care》2004,14(3):177-182
Objective: To evaluate plasma sodium and glucose concentrations in dogs with congestive heart failure (CHF) prior to treatment and evaluate the differences between survivors and non‐survivors. Design: Retrospective study. Animals: Fifty‐nine dogs with CHF prior to receiving cardiac medication. Interventions: None. Measurements and main results: The mean plasma sodium concentration in dogs with CHF was below the reference range (144–156 mmol/L) and significantly lower (P=0.009) in non‐survivors (141±6 mmol/L) compared with survivors (147±4 mmol/L). The mean plasma glucose concentration was above the reference range (76–117 mg/dL) and significantly higher (P=0.004) in non‐survivors (128±52 mg/dL) compared with survivors (100±13 mg/dL). Forty‐four percent of non‐survivors had concurrent low plasma sodium and high plasma glucose concentrations, whereas no survivors had both abnormalities (P<0.0001). Conclusions: Lower plasma sodium and higher plasma glucose are associated with a worse outcome in dogs with CHF. 相似文献
32.
Julie M. Barr BS Safdar A. Khan DVM MS PhD DABVT Sheila M. McCullough DVM MS DACVIM Petra A. Volmer DVM MS DABVT DABT 《Journal of Veterinary Emergency and Critical Care》2004,14(3):196-202
Objective: To correlate the sodium chloride dosage and the serum sodium concentration to clinical signs, to determine if the dosage of homemade play dough (and, therefore, sodium chloride) is the most reliable way to predict clinical signs and prognosis, and to review previously reported treatment options. Design: Retrospective case series. Animals: Fourteen dogs with a history of homemade play dough ingestion. Procedure: Cases were examined for each animal's signalment including body weight, age, approximate amount of play dough ingested, the estimated sodium chloride dosage, clinical signs, serum sodium concentration, and outcome when available. The literature was reviewed to determine pathophysiology and treatment regimens. Results: Twelve of 14 dogs (86%) that ingested homemade play dough showed clinical signs. Vomiting (9 of 14, 64%), polydipsia, and seizures (4 of 14 each, 29%) were the most common signs followed by polyuria, tremors (3 of 14 each, 21%), and hyperthermia (2 of 14, 14%). The lowest calculated dosage associated with objective clinical signs was 1.9 g/kg. Seizures were reported in all animals with serum sodium levels greater than 180 mEq/L. Conclusions and clinical relevance: Homemade play dough ingestion can be a serious and life‐threatening problem. Many factors can contribute to the toxicity of homemade play dough. This study indicates that the serum sodium concentration is a more reliable indicator of the clinical course of the toxicity rather than the amount of play dough and, therefore, the dosage of sodium chloride ingested. Treatment should be based on a clinical evaluation of the patient and laboratory results, and consists of controlling seizures, reducing serum sodium concentrations slowly, and supportive care. 相似文献
33.
34.
35.
Prognostic value of echocardiographic indices of left atrial morphology and function in dogs with myxomatous mitral valve disease 
下载免费PDF全文
下载免费PDF全文 36.
Comparative,multidimensional imaging of patent ductus arteriosus and a proposed update to the morphology classification system for dogs 下载免费PDF全文
下载免费PDF全文 37.
Evaluation of individual low‐dose dexamethasone suppression test patterns in naturally occurring hyperadrenocorticism in dogs 下载免费PDF全文
下载免费PDF全文 38.
Effect of dasatinib in a xenograft mouse model of canine histiocytic sarcoma and in vitro expression status of its potential target EPHA2 下载免费PDF全文
下载免费PDF全文 K. Ito R. Miyamoto H. Tani S. Kurita M. Kobayashi K. Tamura M. Bonkobara 《Journal of veterinary pharmacology and therapeutics》2018,41(1):e45-e48
Canine histiocytic sarcoma (HS) is an aggressive and highly metastatic tumor. Previously, the kinase inhibitor dasatinib was shown to have potent growth inhibitory activity against HS cells in vitro, possibly via targeting the EPHA2 receptor. Here, the in vivo effect of dasatinib in HS cells was investigated using a xenograft mouse model. Moreover, the expression status of EPHA2 was examined in six HS cell lines, ranging from insensitive to highly sensitive to dasatinib. In the HS xenograft mouse model, dasatinib significantly suppressed tumor growth, as illustrated by a decrease in mitotic and Ki67 indices and an increase in apoptotic index in tumor tissues. On Western blot analysis, EPHA2 was only weakly detected in all HS cell lines, regardless of sensitivity to dasatinib. Dasatinib likely results in the inhibition of xenograft tumor growth via a mechanism other than targeting EPHA2. The findings of this study suggest that dasatinib is a targeted therapy drug worthy of further exploration for the treatment of canine HS. 相似文献
39.
Repeat patient testing shows promise as a quality control method for veterinary hematology testing 下载免费PDF全文
下载免费PDF全文 Bente Flatland Kathleen P. Freeman 《Veterinary clinical pathology / American Society for Veterinary Clinical Pathology》2018,47(2):252-266
Background
Repeat patient testing‐based quality control (RPT‐QC) is a potential method for veterinary laboratories (eg, that have a limited budget for quality commercial control material [QCM] or that wish to use material with a species‐specific matrix).Objectives
To determine whether total error (TEa), probability of error detection (Ped), and probability of false rejection (Pfr) similar to that achievable with QC materials can be controlled using RPT‐QCMethods
Control limits (WBC, RBC, HGB, HCT, MCV, and PLT) for the Advia 120 (n = 23) and scil Vet ABC (n = 22) were calculated using data from normal canine specimens from a routine caseload. Specimens were measured at accession and again after 24 hours. Control limits were validated using 23 additional canine specimens tested similarly. Achievable TEa, Ped, and Pfr were investigated using the Westgard EZRules3 and compared to those achievable with commercial QCM.Results
Theoretical performance of RPT‐QC and commercial QCM‐QC are similar for 1‐3s with both n = 1 and 1‐3s with n = 2 for all measurands and both instruments. Achievable TEa values for RPT‐QC were close to ASVCP recommendations for most measurands; exceptions were PLT (both instruments) and WBC (scil Vet ABC).Conclusions
Repeat patient testing‐based quality control advantages include a species‐specific matrix, low‐cost, and absence of QC material deterioration over time (since a fresh specimen is used each day). A potential disadvantage is daily access to normal canine specimens. A challenge is determining control limits, which has a subjective element. Further study is needed to confirm actual RPT‐QC performance and to determine if RPT‐QC with abnormal patient specimens is feasible. 相似文献40.